The panel is designed to detect 13 drug resistance genes in a blood sample. This can include genes that indicate a resistance to antimicrobial drugs that can affect the treatment of bacterial infections.
“Fighting antimicrobial resistance not only requires the development of rapid diagnostics, like the T2Resistance Panel, but also requires access to these innovations so they can make a positive impact on as many patients as possible,” CEO John McDonough said in a news release. “We are grateful that with the invaluable help of CARB-X’s funding, patients in Europe can start benefiting clinically from the early detection of antibiotic-resistant bloodstream infections.”
The T2Resistance Panel was developed with support from CARB-X. In order to receive funding, T2 Biosystems had to show an advisory panel consisting of global experts in the antimicrobial resistance and diagnostic fields that had the potential to improve the detection and diagnosis of drug-resistant bacterial infections.
“We’re proud that we were able to help T2 deliver its technology to market at part of our effort to support the development of rapid diagnostics, antibiotics, vaccines and other products from around the world to address drug-resistant bacteria,” executive director of CARB-X Kevin Outterson said. “This represents a huge step forward with patients, and a critical milestone for CARB-X. Rapid diagnosis of drug-resistant infections is essential to improve appropriate treatment for patients, and to save lives.”
The company won FDA breakthrough device designation in February this year.